These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 19275683)
1. A novel approach to anticancer therapies: peroxisome proliferator activator-receptor-gamma as a new target therapy in the treatment of human urological cancer. Matsuyama M; Yoshimura R Endocr Metab Immune Disord Drug Targets; 2009 Mar; 9(1):76-83. PubMed ID: 19275683 [TBL] [Abstract][Full Text] [Related]
2. [Relationship between peroxisome proliferator activator-receptor (PPAR) and urological cancer]. Yoshimura R; Nakatani T Nihon Rinsho; 2005 Apr; 63(4):672-8. PubMed ID: 15828236 [TBL] [Abstract][Full Text] [Related]
3. Peroxisome Proliferator-Activated Receptor-gamma Is a Potent Target for Prevention and Treatment in Human Prostate and Testicular Cancer. Matsuyama M; Yoshimura R PPAR Res; 2008; 2008():249849. PubMed ID: 18317513 [TBL] [Abstract][Full Text] [Related]
4. The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells. Yoshimura R; Matsuyama M; Hase T; Tsuchida K; Kuratsukuri K; Kawahito Y; Sano H; Segawa Y; Nakatani T Int J Mol Med; 2003 Dec; 12(6):861-5. PubMed ID: 14612958 [TBL] [Abstract][Full Text] [Related]
5. Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Inoue K; Kawahito Y; Tsubouchi Y; Kohno M; Yoshimura R; Yoshikawa T; Sano H Biochem Biophys Res Commun; 2001 Sep; 287(3):727-32. PubMed ID: 11563856 [TBL] [Abstract][Full Text] [Related]
6. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Subbarayan V; Sabichi AL; Kim J; Llansa N; Logothetis CJ; Lippman SM; Menter DG Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1710-6. PubMed ID: 15533897 [TBL] [Abstract][Full Text] [Related]
7. Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease. Guan Y Minerva Urol Nefrol; 2002 Jun; 54(2):65-79. PubMed ID: 12185990 [TBL] [Abstract][Full Text] [Related]
8. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Yoshimura R; Matsuyama M; Segawa Y; Hase T; Mitsuhashi M; Tsuchida K; Wada S; Kawahito Y; Sano H; Nakatani T Int J Cancer; 2003 May; 104(5):597-602. PubMed ID: 12594814 [TBL] [Abstract][Full Text] [Related]
9. Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. Hase T; Yoshimura R; Mitsuhashi M; Segawa Y; Kawahito Y; Wada S; Nakatani T; Sano H Urology; 2002 Sep; 60(3):542-7. PubMed ID: 12350514 [TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics? Han S; Roman J Anticancer Drugs; 2007 Mar; 18(3):237-44. PubMed ID: 17264754 [TBL] [Abstract][Full Text] [Related]
12. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Segawa Y; Yoshimura R; Hase T; Nakatani T; Wada S; Kawahito Y; Kishimoto T; Sano H Prostate; 2002 May; 51(2):108-16. PubMed ID: 11948965 [TBL] [Abstract][Full Text] [Related]
13. Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma. Jung TI; Baek WK; Suh SI; Jang BC; Song DK; Bae JH; Kwon KY; Bae JH; Cha SD; Bae I; Cho CH Gynecol Oncol; 2005 May; 97(2):365-73. PubMed ID: 15863131 [TBL] [Abstract][Full Text] [Related]
14. Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma. Park HK; Kim H; Kim HG; Cho YM; Jung WY; Han HS; Hwang TS; Kwon GY; Lim SD J Korean Med Sci; 2015 May; 30(5):533-41. PubMed ID: 25931782 [TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer. Nagata D; Yoshihiro H; Nakanishi M; Naruyama H; Okada S; Ando R; Tozawa K; Kohri K Cancer Detect Prev; 2008; 32(3):259-66. PubMed ID: 18789607 [TBL] [Abstract][Full Text] [Related]
16. The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer. Matsuyama M; Yoshimura R Biologics; 2008 Dec; 2(4):725-32. PubMed ID: 19707453 [TBL] [Abstract][Full Text] [Related]
17. hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. Li Y; Wen X; Spataro BC; Hu K; Dai C; Liu Y J Am Soc Nephrol; 2006 Jan; 17(1):54-65. PubMed ID: 16291834 [TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743 [TBL] [Abstract][Full Text] [Related]
19. [Peroxisome proliferator-actived receptor-gamma ligand troglitazone induces apoptosis in renal cell carcinoma]. Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu XQ; Liu WJ; Guo YL; Wu JP Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 36(2):173-6. PubMed ID: 15100737 [TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy and radiotherapy for urological cancer]. Miyanaga N; Tsukamoto S; Hattori K; Kawai K; Shimazui T; Uchida K; Akaza H Gan To Kagaku Ryoho; 2002 May; 29(5):709-16. PubMed ID: 12040674 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]